The incidence of organ-related symptoms within 14 days after uterine fibroid surgery discharge (disease-specific indicator)
Experts recommend using four indicators to assess the quality of care in medical institutions for uterine fibroid surgery, including the rate of inpatient days exceeding seven, the occurrence of organ damage within 14 days after discharge, the occurrence of organ symptoms within 14 days after discharge, and the readmission rate for surgery-related diagnoses within 14 days after discharge.
Data fields
Yearly、Medical institution code、Name of the medical institution、Preferred category、The number of outpatient visits within 14 days after discharge with symptoms related to the relevant organs.、The number of inpatients diagnosed with and undergoing surgery for uterine fibroids or hysterectomy、The number of patients undergoing uterine fibroid surgery、The incidence of organ-related symptoms within 14 days after discharge from uterine fibroid surgery、The number of reporting physicians、Average patient age、The ratio of patients with severe illness is high.、The number of serious illness cases.、County or City、Townships
Contact person
陳小姐 (02-27065866#3006)
Update frequency
Every June
License
Open Government Data License, version 1.0
Charge
free
Publish date
2025-12-10
Dataset type
System programming interface
Updated time
2025-12-10 10:35
Topic
Other
Service category
Dataset Category
Data archives
Keyword
Medical qualityUterine fibroidsIncidence rategender statistics
Note
File update time: 2025-12-10 10:30:07
Related datasets
- The rate of organ damage within fourteen days after uterine fibroid surgery discharge (disease-specific indicator)
- Within fourteen days after discharge from uterine fibroid surgery, the readmission rate for relevant diagnoses for the surgical procedure (disease-specific measure)
- The ratio of the length of stay for hysteromyoma surgery exceeding seven days (disease-specific indicator)
- Cancer incidence statistics
- The annual incidence of malignant tumors (prostate cancer, lung cancer, colorectal cancer, female breast cancer, cervical cancer).
Applications
No available applications